Liver injury in patients with COVID-19 in comparison to patients with the pandemic influenza A (H1N1) 2009: a population-based study

References

• Kumar MP, Mishra S, Jha DK, et al. Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis. Hepatol Int. 2020;14(5):711–722.
   PubMed Web of Science ®Google Scholar
• Sultan S, Altayar O, Siddique SM, et al. AGA institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19. Gastroenterology. 2020;159(1):320–334.e27.
   PubMed Web of Science ®Google Scholar
• Hajifathalian K, Krisko T, Mehta A, et al. Gastrointestinal and hepatic manifestations of 2019 novel coronavirus disease in a large cohort of infected patients From New York: clinical implications. Gastroenterology. 2020;159(3):1137–1140.e2.
   PubMed Web of Science ®Google Scholar
• Fan Z, Chen L, Li J, et al. Clinical features of COVID-19-Related liver functional abnormality. Clin Gastroenterol Hepatol. 2020;18(7):1561–1566.
   PubMed Web of Science ®Google Scholar
• Qi F, Qian S, Zhang S, et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135–140.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Sookoian S. SARS-CoV-2 virus and liver expression of host receptors: putative mechanisms of liver involvement in COVID-19. Liver Int Off J Int Assoc Study Liver. 2020;40(8):2038–2040.
   PubMed Web of Science ®Google Scholar
• Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529–530.
   PubMed Web of Science ®Google Scholar
• Guan W, Ni Z, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Buckholz AP, Kaplan A, Rosenblatt RE, et al. Clinical characteristics, diagnosis, and outcomes of 6 patients with COVID-19 infection and rhabdomyolysis. Mayo Clin Proc. 2020;95(11):2557–2559.
   PubMed Web of Science ®Google Scholar
• Rivas-García S, Bernal J, Bachiller-Corral J. Rhabdomyolysis as the main manifestation of coronavirus disease 2019. Rheumatology. 2020;59(8):2174–2176.
   PubMed Web of Science ®Google Scholar
• Muhović D, Bojović J, Bulatović A, et al. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Liver Int. 2020;40(8):1901–1905.
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Suzuki T, Sayama M, et al. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. J Infect Chemother. 2021;27(2):390–392.
   PubMed Web of Science ®Google Scholar
• Jothimani D, Vij M, Sanglodkar U, et al. Severe jaundice in a COVID-19 patient-virus or drug? J Clin Exp Hepatol. 2021;11(3):407–408.
   PubMed Web of Science ®Google Scholar
• Kumar P, Kulkarni A, Sharma M, et al. Favipiravir-induced liver injury in patients with coronavirus disease 2019. J Clin Transl Hepatol. 2021;9(2):276–278.
   PubMed Web of Science ®Google Scholar
• Leegwater E, Strik A, Wilms EB, et al. Drug-induced liver injury in a patient with coronavirus disease 2019: potential interaction of remdesivir with P-Glycoprotein inhibitors. Clin Infect Dis. 2021;72(7):1256–1258.
   PubMed Web of Science ®Google Scholar
• Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, et al. Case report: hepatotoxicity associated with the use of hydroxychloroquine in a patient with COVID-19. Am J Trop Med Hyg. 2020;102(6):1214–1216.
   PubMed Web of Science ®Google Scholar
• Huang H, Li H, Chen S, et al. Prevalence and characteristics of hypoxic hepatitis in COVID-19 patients in the intensive care unit: a first retrospective study. Front Med 2020;7 [;:607206.
   Web of Science ®Google Scholar
• Bzeizi K, Abdulla M, Mohammed N, et al. Effect of COVID-19 on liver abnormalities: a systematic review and meta-analysis. Sci Rep Nature Publishing Group. 2021;11(1):10599.
   PubMed Web of Science ®Google Scholar
• Shehab M, Alrashed F, Shuaibi S, et al. Gastroenterological and hepatic manifestations of patients with COVID-19, prevalence, mortality by country, and intensive care admission rate: systematic review and meta-analysis. BMJ Open Gastroenterol. 2021;8(1):e000571.
   PubMed Web of Science ®Google Scholar
• Roussel Uclaf Causality Assessment Method (RUCAM) in Drug Induced Liver Injury - LiverTox - NCBI Bookshelf [Internet]. [cited 2023 Feb 6]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK548272/.
   Google Scholar
• Teschke R, Méndez-Sánchez N, Eickhoff A. Liver injury in COVID-19 patients with drugs as causatives: a systematic review of 996 Dili cases published 2020/2021 based on RUCAM as causality assessment method. IJMS. 2022;23(9):4828.
   Web of Science ®Google Scholar
• Eythorsson E, Helgason D, Ingvarsson RF, et al. Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study. BMJ. 2020;371:m4529.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020;383(18):1724–1734.
   PubMed Web of Science ®Google Scholar
• Hjorleifsson KE, Rognvaldsson S, Jonsson H, et al. Reconstruction of a large-scale outbreak of SARS-CoV-2 infection in Iceland informs vaccination strategies. Clin Microbiol Infect. 2022; 28(6):852–858.
   Google Scholar
• Aithal G, Watkins P, Andrade R, et al. Case definition and phenotype standardization in Drug-Induced liver injury. Clin Pharmacol Ther. 2011;89(6):806–815.
   PubMed Web of Science ®Google Scholar
• Henrion J, Schapira M, Heller FR. Ischemic hepatitis: the need for precise criteria. J Clin Gastroenterol. 1996;23(4):305.
   PubMed Web of Science ®Google Scholar
• Adams DH, Hubscher SG. Systemic viral infections and collateral damage in the liver. Am J Pathol. 2006;168(4):1057–1059.
   PubMed Web of Science ®Google Scholar
• Papic N, Pangercic A, Vargovic M, et al. Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza Other Respir Viruses. 2012;6(3):e2–e5.
   PubMed Web of Science ®Google Scholar
• Shafran N, Issachar A, Shochat T, et al. Abnormal liver tests in patients with SARS-CoV-2 or influenza - prognostic similarities and temporal disparities. JHEP Rep. 2021;3(3):100258.
   PubMedGoogle Scholar
• Pitscheider L, Karolyi M, Burkert FR, et al. Muscle involvement in SARS-CoV-2 infection. Eur J Neurol. 2021;28(10):3411–3417.
   PubMed Web of Science ®Google Scholar
• Gibson SB, Majersik JJ, Smith AG, et al. Three cases of acute myositis in adults following influenza-like illness during the H1N1 pandemic. J Neurosci Rural Pract. 2013;4(1):51–54.
   PubMedGoogle Scholar
• Fadila MF, Wool KJ. Rhabdomyolysis secondary to influenza A infection: a case report and review of the literature. N Am J Med Sci. 2015;7(3):122–124.
   PubMedGoogle Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155–170.
   PubMed Web of Science ®Google Scholar
• De Smet V, Verhulst S, Grunsven L V Single cell RNA sequencing analysis did not predict hepatocyte infection by SARS-CoV-2. J Hepatol. 2020;73(4):993–995.
   PubMed Web of Science ®Google Scholar
• Ragab D, Salah Eldin H, Taeimah M, et al. The COVID-19 cytokine storm; what we know So far. Front Immunol. 2020;11:1446.
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications. Aliment Pharmacol Ther. 2019;49(6):681–701.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–455.
   PubMed Web of Science ®Google Scholar
• Björnsson ES, Bergmann OM, Björnsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144(7):1419–1425. 1425.e1–3; quiz e19–20.
   PubMed Web of Science ®Google Scholar
• Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52(4):584–599.
   PubMed Web of Science ®Google Scholar
• Chen F, Chen W, Chen J, et al. Clinical features and risk factors of COVID-19-associated liver injury and function: a retrospective analysis of 830 cases. Ann Hepatol. 2021;21:100267.
   PubMed Web of Science ®Google Scholar
• Delgado A, Stewart S, Urroz M, et al. Characterisation of drug-induced liver injury in patients with COVID-19 detected by a proactive pharmacovigilance program from laboratory signals. JCM. 2021;10(19):4432.
   Web of Science ®Google Scholar